Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of ICG318 CAR-T in adults with refractory systemic lupus erythematosus
ChiCTR2500100106Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ICG318 in systemic lupus erythematosus (SLE) (6 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence and severity of adverse events and Dose-limiting toxicity incidence. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ICG318
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500100106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100106.